These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37055874)

  • 1. A new application of isoindole fluorophore derivative in sitagliptin antidiabetic medication assay: Application to dosage forms and biological fluid evaluation.
    El Hamd MA; Soltan OM; Abdelrahman KS; Alsaggaf WT; Abu-Hassan AA
    Luminescence; 2023 Jun; 38(6):744-752. PubMed ID: 37055874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrative analytical approach designed for feasible tranexamic acid assay using o-phthalaldehyde as a fluorogenic probe: applications to tablets, ampoules, and urine.
    El Hamd MA; Alshehri S; Abu-Hassan AA
    Luminescence; 2023 Dec; 38(12):1988-1995. PubMed ID: 36764931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of isoindole fluorophore formation for determination of linagliptin in the sole and co-formulated tablets: Application for plasma assay and content uniformity testing.
    Abu-Hassan AA; El Hamd MA; El-Maghrabey MH; Mahdi WA; Alshehri S; Shaaban Mohammed B
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Apr; 291():122390. PubMed ID: 36696863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.
    El-Bagary RI; Elkady EF; Ayoub BM
    Talanta; 2011 Jul; 85(1):673-80. PubMed ID: 21645757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
    Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach based on isoindole formation reaction for sensitive fluorimetric assay of milnacipran in tablets and biological fluids (plasma/urine).
    Abu-Hassan AA; Ali R; Derayea SM
    RSC Adv; 2020 Oct; 10(64):38884-38889. PubMed ID: 35518387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].
    Simonyi G; Ferenci T
    Orv Hetil; 2016 Apr; 157(16):618-22. PubMed ID: 27063429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micellar sensitized Resonance Rayleigh Scattering and spectrofluorometric methods based on isoindole formation for determination of Eflornithine in cream and biological samples.
    Abdel-Lateef MA; Almahri A
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Sep; 258():119806. PubMed ID: 33933938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectroflourometric and spectrophotometric methods for the determination of sitagliptin in binary mixture with metformin and ternary mixture with metformin and sitagliptin alkaline degradation product.
    El-Bagary RI; Elkady EF; Ayoub BM
    Int J Biomed Sci; 2011 Mar; 7(1):62-9. PubMed ID: 23675222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.
    Scherf-Clavel O; Kinzig M; Stoffel MS; Fuhr U; Sörgel F
    J Pharm Biomed Anal; 2019 Oct; 175():112754. PubMed ID: 31336285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrophotometric Determination of Metformin in Different Pharmaceutical Combinations With Glipizide or Sitagliptin in Presence of Toxic Impurities of Metformin.
    Abdallah FF; Magdy F; Abdelaleem EA; Emam AA
    J AOAC Int; 2022 Apr; 105(3):657-664. PubMed ID: 34927693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
    Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
    Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin and metformin--novel combination therapy.
    Seyoum B
    Expert Opin Pharmacother; 2011 Mar; 12(4):641-6. PubMed ID: 21291346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.